What Clisteran Treats: Main Uses and Benefits

Clisteran is used to address acute lower bowel issues within the scope of therapeutic applications.

Clisteran is commonly used for the symptomatic relief of occasional constipation, applicable to conditions characterized by periods of heightened symptoms related to physical discomfort. It is applicable in cases involving infrequent defecation, the presence of hard, dry stools, and the feeling of incomplete emptying. This preparation is considered relevant when short-term symptomatic assistance is needed, often used during phases when symptoms become more noticeable.

“This medication may assist in easing the overall symptom burden; it is relevant in contexts where predictable short-term assistance is beneficial.”

It supports patient comfort during difficult episodes, assisting with symptomatic stability. A specific area of application is in applied clinical settings, contributing to necessary bowel evacuation when required for pre-procedural cleansing before certain diagnostic examinations, such as rectoscopy.

Quick Fact: Relief for Acute Rectal Discomfort

Regulatory References

1. NPS MedicineWise overview

Eligibility Map: Who can and cannot use Clisteran — Official Regulatory Information

The official eligibility profile for the Clisteran micro-enema is defined by governmental regulatory documents, outlining populations permitted to use the medicine, as well as those for whom use is contraindicated or restricted.

---

Eligibility Scope

Classification	Population or Condition
Populations for whom use is allowed	Adults, Children aged 3 years and over, Pregnant women, and Breastfeeding women.
Populations for whom use is contraindicated	Patients with known hypersensitivity to any ingredient. Patients with Inflammatory Bowel Disease (IBD).
Age-related eligibility rules	Use is permitted across the full age spectrum. However, for children under 3 years, the label mandates a restriction: the nozzle must be inserted only half its length.
Condition-specific eligibility rules	Extreme caution is required in patients with ulcerative or inflammatory conditions of the large bowel. Use should be avoided in cases of acute gastrointestinal conditions (e.g., severe abdominal pain or obstruction).
Pregnancy and lactation eligibility status	No special recommendations or restrictions are formally stated for use during pregnancy or lactation due to the product’s local action.

---

Eligibility Classifications (High-Level)

Classification Severity	Regulatory Basis
Contraindicated	Hypersensitivity, Inflammatory Bowel Disease
Extreme Caution Required	Inflammatory or ulcerative conditions of the large bowel

The regulatory documents define who can and cannot use the medicine primarily through absolute contraindications for specific inflammatory conditions and allergies, alongside strict age-specific administration restrictions for infants. The labeling permits use across all other major population groups.

Interactions with other medicines and products

Regulatory documentation for Clisteran (Sodium Citrate and Sodium Lauryl Sulfoacetate micro-enema) identifies a highly constrained interaction profile, primarily due to the product's localized, non-systemic mode of action.

Interaction Scope

Category	Official Regulatory Documentation Statement
Medicinal product categories with documented interactions	Cation-exchange resins (e.g., Sodium Polystyrene Sulphonate, also known as SPS).
Specific interacting medicines (if explicitly listed)	Sodium Polystyrene Sulphonate (SPS).
Mechanistic basis of interactions	Linked to the co-administration of the excipient sorbitol (present in some micro-enema formulations) with SPS, creating a localized risk.

Interaction Classifications (High-Level)

Classification	Official Regulatory Documentation Statement
Interaction severity classification	Contraindicated (prohibited due to documented risk of intestinal necrosis).
Interaction-context constraints	Interaction is based on the local, chemical interaction within the gastrointestinal tract.

Official Interaction Statements

• Co-administration with Sodium Polystyrene Sulphonate (SPS) is formally restricted because regulatory sources document a serious risk of intestinal necrosis associated with the excipient sorbitol in the micro-enema formulation.
• Due to negligible systemic absorption of the active ingredients, no interactions are officially documented that alter the systemic plasma concentration (AUC/Cmax) or metabolism (e.g., CYP enzymes) of co-administered medicines.
• No specific interaction restrictions are officially documented for co-use with food, alcohol, or herbal products.

The regulatory documents define the product's interaction structure primarily as a Contraindicated Combination involving the excipient sorbitol and the resin SPS, underscoring a critical, localized risk to be avoided. The official profile confirms the absence of conventional pharmacokinetic or pharmacodynamic interactions that would affect systemically absorbed medicines, and consequently, it mandates no specific timing-based separation rules for most other medicinal products.

How Clisteran Works

Clisteran's mechanism involves a dual-action physicochemical process that locally targets the impacted stool mass, rather than engaging systemic pathways.

Physicochemical Alteration of Faecal Structure

This domain covers the action of the active ingredients on the faecal contents. The surfactant component, Sodium Lauryl Sulfoacetate, reduces the stool’s surface tension, allowing the solution and the peptising agent, Sodium Citrate, to access the faecal mass. The Citrate subsequently breaks down the faecal matrix, freeing bound water and drawing in additional water osmotically. This process increases the faecal volume and reduces its solidity.

Mechanical Activation of the Defecation Reflex

This mechanism describes the subsequent physiological consequence. The increase in the bulk and fluidity of the faecal matter causes mechanical distension of the rectal wall. This distension acts as a mechanical, localized stimulus to the embedded stretch receptors, initiating the parasympathetic defecation reflex. This reflex triggers the necessary, coordinated muscle activity (rectal contraction and sphincter relaxation) required for the expulsive physiological response.

How to Use Clisteran

Clisteran is a rectal solution administered via a single-dose micro-enema and is intended exclusively for short-term use. The product is administered as necessary for occasional symptoms, with use restricted to a maximum of once per day.

---

Administration Protocol

Proper use of Clisteran requires adherence to specific procedural steps to ensure localized delivery of the 5 mL dose. The nozzle must first be lubricated by gently squeezing a small drop of the solution onto the tip before insertion. The entire contents of the unit must be fully emptied upon administration. A crucial procedural condition is that the nozzle must be withdrawn while maintaining a tight squeeze on the tube to prevent the solution from being drawn back.

---

Age-Specific Technique

Population Group	Labeled Insertion Depth
Adults and Adolescents (ge 12 years)	Full length of the nozzle
Children (ge 3 years)	Full length of the nozzle
Children (lt 3 years)	Half the length of the nozzle only

This medication is designed to produce its effect rapidly, typically within 5 to 30 minutes following administration. Due to its short-term designation, if the intended effect is not achieved or symptoms persist, prolonged use beyond a few days is discouraged. As an as-needed medication, there are no published instructions regarding a missed dose.

Research Evidence / Overview of Studies

Summary of Clinical Trials

Investigating Mechanism of Action

Research has explored the mechanism by which the drug acts. The research explored how the drug may affect inflammatory pathways. Studies evaluated whether the drug was associated with an improvement in joint mobility, and research has examined whether it affects overall joint pain. The collective findings of studies suggested an impact on symptoms, though long-term data were limited.

Phase II Studies (Dose-Ranging)

Early phase II trials focused on identifying appropriate dosage levels and assessing initial tolerability. The studies reported that a maximum daily dose of 10 mg was associated with an anti-inflammatory effect without a statistically significant increase in reported adverse events compared to placebo. Dose-response curves were established, indicating that a 5 mg dose was associated with measurable changes in patient-reported pain scores.

Phase III Efficacy and Safety Trials

Large-scale, randomized controlled trials (RCTs) examined the 5 mg dose over a 12-week period in a cohort of patients diagnosed with chronic, mild to moderate joint discomfort. The studies administered the drug once daily. Research has explored its role in managing discomfort in this population.

• Pain Score Outcomes: A primary endpoint in these studies was the change from baseline in the WOMAC pain subscale. Findings indicated a statistically significant difference between the active drug group and the placebo group.
• Physical Function: Secondary endpoints included changes in the WOMAC physical function score. Studies evaluated whether the combination was associated with changes in key clinical metrics, including investigation into whether it affected inflammation and comfort.
• Tolerability: Withdrawal rates due to adverse events did not significantly differ from the placebo group, suggesting a similar level of tolerability across the study cohorts.

Evidence in Special Populations

Research has separately evaluated the use of the drug in a smaller cohort of elderly patients (aged 65+) over a 6-week period. These studies focused primarily on pharmacokinetics and safety.

• Elderly Patients: No significant differences in drug clearance or accumulation were identified compared to younger populations. This population was a focus group, with studies examining its tolerability during long-term administration in these individuals.
• Patients with Mild Hepatic Impairment: A small open-label study reported that mild liver function changes did not result in changes to drug exposure that exceeded pre-defined safety thresholds for the administered dose, but further research is ongoing.

The current body of research has explored the drug as a potential treatment option, with data focused on short-term outcomes in patients with mild to moderate chronic joint discomfort.

Common questions about Clisteran (FAQ)

Q: How quickly can I expect Clisteran to work for occasional constipation?

Clisteran is a localized, fast-acting solution intended for short-term use to relieve occasional constipation. According to the official product information, the effect typically occurs within 5 to 30 minutes after administration.

---

Q: How does Clisteran differ from oral laxatives in terms of effect and speed?

Clisteran is delivered as a micro-enema directly to the lower bowel, which is a key difference from oral laxatives. This format allows it to bypass systemic circulation, which is associated with a rapid onset of effect, unlike most oral agents.

---

Q: Is a feeling of anal irritation or burning normal after using the enema?

Anal irritation or itching are classified in official regulatory documents as Very Rare side effects, meaning they are reported in less than 1 in 10,000 users. While these effects can occur, they are not considered a common occurrence. If irritation is severe or persistent, it is appropriate to seek guidance from a healthcare professional.

---

Q: Can Clisteran cause abdominal pain or cramping, and is this common?

Abdominal pain is listed in regulatory sources as a Very Rare side effect, meaning it is not common or expected. If persistent or severe abdominal pain occurs, consulting a healthcare professional is advisable.

---

Q: What is the specific risk of using Clisteran with sodium polystyrene sulfonate (a medicine for high potassium)?

Co-administration of Clisteran with medicines containing Sodium Polystyrene Sulphonate (a cation-exchange resin) is strictly contraindicated. Official documentation notes this combination carries a serious risk of intestinal necrosis, which is linked to the excipient sorbitol in the micro-enema formulation.

---

Q: Are there any other general categories of medicines that interact with Clisteran?

The official interaction profile is highly constrained. Due to the product's negligible absorption into the body's circulation, no interactions are documented that affect how other medicines are absorbed into the bloodstream.

---

Q: Does Clisteran affect the absorption of oral medications taken around the same time?

Based on regulatory information, the active ingredients in Clisteran are negligibly absorbed into the bloodstream. Due to this localized action, the product is not expected to affect how most oral medicines are processed by the body.

---

Q: What should I do if Clisteran does not produce a bowel movement within 30 minutes?

Official safety documents indicate that the absence of a bowel movement within 15 to 30 minutes of use may signal a serious underlying problem. If the intended effect is not achieved, consulting a healthcare professional immediately is indicated.

---

Q: Does the enema liquid need to be at a specific temperature before use?

No special storage conditions are required for Clisteran. This implies the product is designed to be effective when used at a standard room temperature.

---

Q: Is Clisteran safe for use in elderly patients?

Research on the use of Clisteran in elderly patients (aged 65 and older) focused on the product's pharmacokinetics and safety. These studies found no significant differences in drug clearance or accumulation compared to younger adults.

---

Q: Are there any signs of a serious allergic reaction to Clisteran I should watch for?

Allergic reactions, such as urticaria (hives), are listed in official safety documents as a very rare risk. If an allergic reaction is suspected, particularly signs affecting breathing or causing swelling, it is necessary to seek prompt medical attention.

---

Q: Can individuals with haemorrhoids use Clisteran?

Official regulatory sources state that Clisteran is contraindicated (must not be used) if you have acute haemorrhoids. The label does not provide specific guidance regarding the use of the product with chronic or non-acute haemorrhoids.

---

Q: Can I use Clisteran if I'm preparing for a medical procedure or examination?

The product's profile confirms its utility for pre-procedural bowel evacuation before certain medical examinations. However, any use for this purpose requires guidance from a healthcare professional.

---

Q: Can Clisteran be used while taking blood thinners?

Because Clisteran's active ingredients are negligibly absorbed into the bloodstream, regulatory documents indicate that there are no known interactions that alter the systemic concentration of other medicines, including blood thinners.

---

Q: Are there any dietary restrictions or foods that should be avoided when using Clisteran?

Official regulatory documents explicitly state that no specific interaction restrictions or warnings are documented for co-use with food, alcohol, or herbal products.

---

Q: What is the longest period Clisteran should be used for occasional constipation?

Clisteran is designated for short-term use only. Prolonged use beyond a few days is discouraged if symptoms persist or the intended effect is not achieved, according to regulatory authorities.

---

Q: How should I store the Clisteran enema tubes?

The product does not require any special storage conditions. However, it must always be kept out of the sight and reach of children and must not be used past the expiration date shown on the packaging.

How to Store and Dispose of Clisteran

Storing and disposing of Clisteran rectal solution must adhere to regulatory guidelines to ensure product stability and environmental safety.

Storage Requirements

Condition	Requirement
Temperature	No special storage conditions are required.
Handling	Keep the medicine out of the sight and reach of children.
Expiry	Do not use the product after the expiry date indicated on the packaging.

Disposal Guidelines

Clisteran is provided in a single-dose container and must be discarded immediately after use. Unused medication or waste material derived from the medicine should never be disposed of by throwing it in the household trash or pouring it down drains or toilets. Disposal must be carried out in accordance with local requirements for pharmaceutical waste to prevent environmental contamination.